University of Nebraska at Omaha

DigitalCommons@UNO
Psychology Faculty Publications

Department of Psychology

7-2002

Anxiolytic Effect of Melatonin in Premenstrual
Dysphoric Disorder
Jonathan Bruce Santo
University of Nebraska at Omaha, jsanto@unomaha.edu

S. Lo
McGill University

P. L'Esperance
McGill University

D. B. Boivin
McGill University

Follow this and additional works at: https://digitalcommons.unomaha.edu/psychfacpub
Part of the Psychology Commons
Recommended Citation
Santo, Jonathan Bruce; Lo, S.; L'Esperance, P.; and Boivin, D. B., "Anxiolytic Effect of Melatonin in Premenstrual Dysphoric Disorder"
(2002). Psychology Faculty Publications. 35.
https://digitalcommons.unomaha.edu/psychfacpub/35

This Article is brought to you for free and open access by the Department
of Psychology at DigitalCommons@UNO. It has been accepted for
inclusion in Psychology Faculty Publications by an authorized
administrator of DigitalCommons@UNO. For more information, please
contact unodigitalcommons@unomaha.edu.

Anxiolytic Effect of Melatonin in Premenstrual Dysphoric Disorder
J.B. Santo, S. Lo, P. L'Espcirance, D.B. Boivin*
Douglas Hospital Research Center, McGill University, Montreal, Que., Canada
Increases in anxiety levels during the late-luteal phase of the menstrual cycle form important diagnostic
criteria of premenstrual dysphoric disorder (PMDD) (1). Evidence exists to support the hypothesis that
tolerance to endogenous levels of melatonin might occur during the luteal phase in PMDD (2, 3). It was
hypothesized that slow release (SR) melatonin administration during the luteal phase of the menstrual
cycle of participants with PMDD could significantly lower anxiety levels measured by self-report.
Three participants (aged 32-41) diagnosed with PMDD were examined for a period of >6 menstrual
cycles. Daily anxiety self-report scales ranging from 0 to 100 confirmed PMDD. After 3 menstrual cycles,
participants were administered 2 mg SR melatonin 1 h prior to bedtime during the luteal phase for 3
menstrual cycles. Mid-follicular (second week) and late-luteal (last week) scores were compared
between baseline and treatment conditions using a Wilcoxon signed ranks test.
Anxiety across the Menstrual Cycle

Baseline anxiety was 19.76 (S.D.=24.57) during the mid-follicular phase and 41.23 (S.D.=33.84) during
the late-luteal phase. This represents a 473% increase across the menstrual cycle (P< 0.0001). Treatment
period anxiety levels during the late-luteal phase were 20.5 (S.D.=24.63), thus reduced to 50% of the
baseline values of the luteal phase. Treatment period results from the late-luteal phase were
comparable to those of the mid-follicular phase (P=0.523).
Anxiety does vary significantly across the menstrual cycle in women with PMDD. Exogenous melatonin
administration exerted a significant anxiolytic effect in participants. Whether melatonin administration
counteracts a reduced activity of endogenous melatonin levels or rather exerts an independent
pharmacological anxiolytic effect remains unclear. Despite these concerns, these results support the
proposed hypothesis and suggest that reduced melatonin secretion and/or sensitivity may play a role in
PMDD. A placebo trial and a control group is required to better understand the mediating factors
involved.
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